Compare Quest Diagnostics Inc (DGX) vs Huntington Ingalls Industries Inc (HII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Huntington Ingalls Industries Inc — how do they compare? Quest Diagnostics Inc trades at $205.48 (market cap $22.80B), while Huntington Ingalls Industries Inc trades at $283 (market cap $11.03B). The key difference: Quest Diagnostics Inc is far larger — about 2.1× Huntington Ingalls Industries Inc's market cap, and Huntington Ingalls Industries Inc pays the higher dividend (1.97%). Which is the better fit depends on your goals.
| DGX | HII | |
|---|---|---|
Market Cap | $22.80B | $11.03B |
Sector | Health | Technology |
52-Week High | $216.02 | $453.73 |
52-Week Low | $166.42 | $252.93 |
Enterprise Value | $28.82B | $13.75B |
Dividend Yield | 1.67% | 1.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
HII trades at $284.86, down 0.43% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company shows stable fundamentals with a P/E of 18.19 and net income margin of 4.71%, supported by recent earnings beats. Recent news highlights contract awards and leadership additions, reinforcing its defense sector presence.
The outlook is cautiously optimistic with a consensus price target of $354.50, implying significant upside. Risks include execution on new contracts and defense budget dependencies, but analyst sentiment leans positive with 44% buy ratings. The upcoming Q2 2026 earnings report on July 30 will be a key catalyst for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →
